Interactions between ghrelin, leptin and IGF-I affect metabolic syndrome and early atherosclerosis

References

• Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001; 409: 194–8
   PubMed Web of Science ®Google Scholar
• Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes. 2001; 50: 227–32
   PubMed Web of Science ®Google Scholar
• Tschöp M, Viswanath D, Weyer C, Tataranni PA, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001; 50: 707–9
   PubMed Web of Science ®Google Scholar
• Leyva F, Godsland IF, Ghatei M, Proudler AJ, Aldis S, Walton C, et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol. 1998; 18: 928–33
   PubMed Web of Science ®Google Scholar
• Gabriely I, Ma XH, Yang XM, Rossetti L, Barzilai N. Leptin resistance during aging is independent of fat mass. Diabetes. 2002; 51: 1016–21
   PubMedGoogle Scholar
• Valle M, Gascon F, Martos R, Bermudo F, Ceballos P, Suanes A. Relationship between high plasma leptin concentrations and metabolic syndrome in obese pre-pubertal children. Int J Obes Relat Metab Disord. 2003; 27: 13–8
   Web of Science ®Google Scholar
• Franks PW, Brage S, Luan J, Ekelund U, Rahman M, Farooqi IS, et al. Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obes Res. 2005; 13: 1476–84
   PubMedGoogle Scholar
• Langenberg C, Bergstrom J, Laughlin GA, Barrett-Connor E. Ghrelin and the metabolic syndrome in older adults. J Clin Endocrinol Metab. 2005; 90: 6448–53
   PubMedGoogle Scholar
• Ukkola O, Pöykkö SM, Kesäniemi YA. Low plasma ghrelin concentration is an indicator of the metabolic syndrome. Ann Med. 2006; 38: 274–9
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care. 2007; 30: 1200–5
   PubMed Web of Science ®Google Scholar
• Pöykkö SM, Kellokoski E, Hörkkö S, Kauma H, Kesäniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes. 2003; 52: 2546–53
   PubMed Web of Science ®Google Scholar
• Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402: 656–60
   PubMed Web of Science ®Google Scholar
• Pöykkö SM, Ukkola O, Kauma H, Kellokoski E, Hörkkö S, Kesäniemi YA. The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes. Diabetologia. 2005; 48: 309–16
   PubMedGoogle Scholar
• Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002; 106: 939–44
   PubMed Web of Science ®Google Scholar
• Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2004; 89: 114–10
   PubMed Web of Science ®Google Scholar
• Pöykkö SM, Kellokoski E, Ukkola O, Kauma H, Päivänsalo M, Kesäniemi YA, et al. Plasma ghrelin concentrations are positively associated with carotid artery atherosclerosis in males. J Intern Med. 2006; 260: 43–52
   PubMed Web of Science ®Google Scholar
• Hietaniemi M, Pöykkö SM, Ukkola O, Päivänsalo M, Kesäniemi YA. IGF-I concentrations are positively associated with carotid artery atherosclerosis in women. Ann Med. 2005; 37: 373–82
   PubMed Web of Science ®Google Scholar
• Rantala AO, Kauma H, Lilja M, Savolainen MJ, Reunanen A, Kesäniemi YA. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med. 1999; 245: 163–74
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15: 539–53
   PubMed Web of Science ®Google Scholar
• Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001; 50: 1714–9
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet. 2005; 366: 1059–62
   PubMed Web of Science ®Google Scholar
• Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000; 85: 2402–10
   PubMed Web of Science ®Google Scholar
• Kohno D, Gao HZ, Muroya S, Kikuyama S, Yada T. Ghrelin directly interacts with neuropeptide-Y-containing neurons in the rat arcuate nucleus: Ca2+ signaling via protein kinase A and N-type channel-dependent mechanisms and cross-talk with leptin and orexin. Diabetes. 2003; 52: 948–56
   PubMed Web of Science ®Google Scholar
• Emilsson V, Liu YL, Cawthorne MA, Morton NM, Davenport M. Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes. 1997; 46: 313–6
   Web of Science ®Google Scholar
• Van Gaal LF, Wauters MA, Mertens IL, Considine RV, De Leeuw IH. Clinical endocrinology of human leptin. Int J Obes Relat Metab Disord. 23 Suppl 1999; 1: 29–36
   Google Scholar
• Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol. 2000; 143: 293–311
   PubMed Web of Science ®Google Scholar
• Wierup N, Svensson H, Mulder H, Sundler F. The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas. Regul Pept. 2002; 107: 63–9
   PubMed Web of Science ®Google Scholar
• Prado CL, Pugh-Bernard AE, Elghazi L, Sosa-Pineda B, Sussel L. Ghrelin cells replace insulin-producing beta cells in two mouse models of pancreas development. Proc Natl Acad Sci U S A. 2004; 101: 2924–9
   PubMed Web of Science ®Google Scholar
• Murata M, Okimura Y, Iida K, Matsumoto M, Sowa H, Kaji H, et al. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem. 2002; 277: 5667–74
   PubMed Web of Science ®Google Scholar
• Boquist S, Ruotolo G, Skoglund-Andersson C, Tang R, Bjorkegren J, Bond MG, et al. Correlation of serum IGF-I and IGFBP-1 and -3 to cardiovascular risk indicators and early carotid atherosclerosis in healthy middle-aged men. Clin Endocrinol (Oxf). 2007; 10:68: 51–8
   Google Scholar
• Ruotolo G, Bavenholm P, Brismar K, Efendic S, Ericsson CG, de Faire U, et al. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. J Am Coll Cardiol. 2000; 35: 647–54
   PubMed Web of Science ®Google Scholar
• Gonzalez B, Lamas S, Melian EM. Cooperation between low density lipoproteins and IGF-I in the promotion of mitogenesis in vascular smooth muscle cells. Endocrinology. 2001; 142: 4852–60
   Google Scholar
• Yamamoto M, Yamamoto K. Growth regulation in primary culture of rabbit arterial smooth muscle cells by platelet-derived growth factor, insulin-like growth factor-I, and epidermal growth factor. Exp Cell Res. 1994; 212: 62–8
   PubMed Web of Science ®Google Scholar
• Delafontaine P, Lou H. Angiotensin II regulates insulin-like growth factor I gene expression in vascular smooth muscle cells. J Biol Chem. 1993; 268: 16866–70
   Google Scholar
• Bayes-Genis A, Conover CA, Schwartz RS. The insulin-like growth factor axis: A review of atherosclerosis and restenosis. Circ Res. 2000; 86: 125–30
   PubMed Web of Science ®Google Scholar
• Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya H, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol. 2001; 280: R1483–7
   PubMed Web of Science ®Google Scholar
• Enomoto M, Nagaya N, Uematsu M, Okumura H, Nakagawa E, Ono F, et al. Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone-releasing peptide, in healthy humans. Clin Sci (Lond) 2003; 105: 431–5
   PubMed Web of Science ®Google Scholar
• Soeki T, Kishimoto I, Schwenke DO, Tokudome T, Horio T, Yoshida M, et al. Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. Am J Physiol Heart Circ Physiol. 2008; 294: H426–32
   PubMed Web of Science ®Google Scholar
• Li L, Zhang LK, Pang YZ, Pan CS, Qi YF, Chen L, et al. Cardioprotective effects of ghrelin and des-octanoyl ghrelin on myocardial injury induced by isoproterenol in rats. Acta Pharmacol Sin. 2006; 27: 527–35
   PubMed Web of Science ®Google Scholar
• Isgaard J, Johansson I. Ghrelin and GHS on cardiovascular applications/functions. J Endocrinol Invest. 2005; 28: 838–42
   PubMedGoogle Scholar
• Cao JM, Ong H, Chen C. Effects of ghrelin and synthetic GH secretagogues on the cardiovascular system. Trends Endocrinol Metab. 2006; 17: 13–8
   PubMedGoogle Scholar
• Xu XB, Pang JJ, Cao JM, Ni C, Xu RK, Peng XZ, et al. GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure. Am J Physiol Heart Circ Physiol. 2005; 289: H1643–51
   Google Scholar
• Chang L, Ren Y, Liu X, Li WG, Yang J, Geng B, et al. Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. J Cardiovasc Pharmacol. 2004; 43: 165–70
   PubMed Web of Science ®Google Scholar
• Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R. Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart. Basic Res Cardiol. 2003; 98: 401–5
   PubMed Web of Science ®Google Scholar
• Pemberton CJ, Tokola H, Bagi Z, Koller A, Pontinen J, Ola A, et al. Ghrelin induces vasoconstriction in the rat coronary vasculature without altering cardiac peptide secretion. Am J Physiol Heart Circ Physiol. 2004; 287: H1522–9
   PubMed Web of Science ®Google Scholar
• Katugampola SD, Pallikaros Z, Davenport AP. 125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis. Br J Pharmacol. 2001; 134: 143–9
   PubMedGoogle Scholar